Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Journal:

The Lancet Oncology

Published:

2026-01-08

DOI:

10.1016/s1470-2045(25)00653-9

Affiliations:

30

Authors:

31

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	7.000000	0.23
Legend Biotech USA, Inc., United States of America (USA)	3.000000	0.10
Johnson & Johnson, Belgium, Belgium	1.000000	0.03
Stanford University, United States of America (USA)	1.000000	0.03
Centre d’Investigation Clinique de Poitiers (CIC de Poitiers), France	1.000000	0.03
University Hospital of Würzburg (UKW), JMU, Germany	1.000000	0.03
University College London Hospitals NHS Foundation Trust (UCLH), United Kingdom (UK)	1.000000	0.03
Healthcare Research Institute of Navarre (IdiSNA), Spain	1.000000	0.03
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.03
Johnson & Johnson, Argentina, Argentina	1.000000	0.03
Johnson & Johnson, Switzerland, Switzerland	1.000000	0.03
Johnson & Johnson Medical (China) Ltd., China	1.000000	0.03
Tel Aviv Sourasky Medical Center, Israel	1.000000	0.03
Centre Hospitalier Lyon-Sud, HCL, France	1.000000	0.03
Amsterdam UMC, Location VUmc, Netherlands	1.000000	0.03
IJC-IGTP-ICO, Spain	1.000000	0.03
Johnson & Johnson, Germany, Germany	1.000000	0.03
Medical College of Wisconsin (MCW), United States of America (USA)	1.000000	0.03
Royal Prince Alfred Hospital (RPAH), USYD, Australia	1.000000	0.03
Institute of Biomedical Research of Salamanca (IBSAL), Spain	0.500000	0.02
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain	0.500000	0.02
Hospital Universitario 12 de Octubre, Spain	0.500000	0.02
Spanish National Cancer Research Centre (CNIO), Spain	0.500000	0.02
Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), France	0.500000	0.02
SIRIC ILIAD, France	0.500000	0.02
Peter MacCallum Cancer Centre (Peter Mac), Australia	0.333333	0.01
Royal Melbourne Hospital (RMH), Australia	0.333333	0.01
The University of Melbourne (UniMelb), Australia	0.333333	0.01

Interested in Oncology and Carcinogenesis?